Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA warns Actelion for misleading Tracleer flash card

This article was originally published in Scrip

Executive Summary

A flash card used by Actelion Pharmaceuticals sales reps which makes a direct comparison between the company's pulmonary arterial hypertension treatment Tracleer (bosentan) and sildenafil (Pfizer's Revatio) is misleading because it presents an unsubstantiated superiority claim and omits serious and important risk information associated with the use of Tracleer, the US FDAsays in a warning letter. The promotion focused on four considerations a practitioner might use when selecting a therapy for PAH, but the agency said the four questions asked could not be used to support the superiority of Tracleer. Additionally, the promotion omitted material information on Tracleer's serious risks "that are highly relevant to any decision about whether to prescribe Tracleer or sidenafil", the agency wrote. Tracleer is approved under a risk management programme (including restricted distribution) and has a boxed warning due to the risks of potential liver injury and major birth defects – restrictions and warnings which are not part of the sildenafil product label. The FDA requests that Actelion submit a corrective messaging plan; Actelion has stated that it intends to fully comply with the agency's request.

You may also be interested in...

ChemoCentryx cuts price to get $45M IPO away

ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (, 7 February 2012).

Ampio raises $16.9M as it advances PhIII premature ejaculation drug

Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.

Money talks: Verastem leverages IPO to build cancer stem cell pipeline

Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts